Agios Pharmaceuticals, Inc.
Financials
Valuation Metrics
Agios Pharmaceuticals, Inc.'s Market Cap is $1.97B. At end of 2025 it was $1.59B. Ranked #2035 of 3,121 in US market (top 65%), #781 of 1,463 on NASDAQ (top 53%), #142 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.97B | US#2,035/3,121 Sec#142/266 |
| Revenue | $98M | US#2,711/3,121 Sec#128/266 |
| Net Income | $-411M | US—/3,121 Sec—/266 |
| Total Assets | $1.11B | US#2,428/3,121 Sec#96/266 |
| Net Assets | $1.03B | US#1,752/3,121 Sec#64/266 |
| Employees | 540 | US#2,249/3,121 Sec#79/266 |
| Value | ||
| P/B | 1.92x | US#1,210/3,121 Sec#46/266 |
| P/S | 20.00x | US#2,848/3,121 Sec#145/266 |
| FCF Yield | -18.57% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -40.09% | US#2,632/3,121 Sec#137/266 |
| ROA | -37.11% | US#2,932/3,121 Sec#180/266 |
| Op. Margin | -466.78% | US#2,805/3,121 Sec#154/266 |
| Revenue Growth | 140.58% | US#70/3,121 Sec#26/266 |
| Earnings Growth | -163.27% | US#1,943/3,121 Sec#61/266 |
| Financial Health | ||
| Debt Ratio | 8.03% | US#81/3,121 Sec#37/266 |
| Total Debt | $31M | US#2,692/3,121 Sec#175/266 |
| FCF | $-365M | US#2,874/3,121 Sec#243/266 |
| Cash | $100M | US#2,230/3,121 Sec#175/266 |
| Current Ratio | 10.22x | US#248/3,121 Sec#78/266 |
| Performance | ||
| 1Y Return | -12.86% | US#2,050/3,121 Sec#196/266 |
| 1M Return | -5.84% | US#1,261/3,121 Sec#116/266 |
| From 52W High | -28.11% | US#1,889/3,121 Sec#144/266 |
| 1Y MDD | -50.89% | US#2,496/3,121 Sec#183/266 |
| Trading | ||
| Volume | 1,381,629 shares | US#2,011/3,121 Sec#213/266 |
| Trading Value | $46M | US#1,998/3,121 Sec#156/266 |
| Per Share | ||
| EPS | $-6.92 | US—/3,121 Sec—/266 |
| BPS | $17.25 | US#1,396/3,121 Sec#39/266 |
Company Info
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.